|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-4-29
|
|
pubmed:abstractText |
Hip fracture is an important and costly problem. Bisphosphonate therapy prevents hip and other fractures among women with established osteoporosis, but there are few published economic evaluations of this treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1460-2725
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
305-11
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11978902-Aged,
pubmed-meshheading:11978902-Calcium Channel Blockers,
pubmed-meshheading:11978902-Cost-Benefit Analysis,
pubmed-meshheading:11978902-Etidronic Acid,
pubmed-meshheading:11978902-Female,
pubmed-meshheading:11978902-Hip Fractures,
pubmed-meshheading:11978902-Humans,
pubmed-meshheading:11978902-Models, Econometric,
pubmed-meshheading:11978902-Osteoporosis, Postmenopausal,
pubmed-meshheading:11978902-Quality-Adjusted Life Years,
pubmed-meshheading:11978902-Randomized Controlled Trials as Topic,
pubmed-meshheading:11978902-Time Factors
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
The cost utility of bisphosphonate treatment in established osteoporosis.
|
|
pubmed:affiliation |
Department of Health Sciences & Centre for Health Economics, University of York, York.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
